Twelve‐month outcomes following temperature‐controlled radiofrequency treatment of the septal swell body for nasal airway obstruction
International Forum of Allergy & Rhinology · 2024-10 · 14 (10) · 1549-1557
DOI: 10.1002/alr.23383 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 06.06.2024. Verfasst von Jordan Pritikin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chicago Nasal & Sinus Center, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Nasal Obstruction, Nasal Septum, Hypertrophy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Aerin Medical.
Abstract (Originalsprache)
Background
Improved nasal airway obstruction (NAO) symptoms were reported at 3 months following temperature‐controlled radiofrequency (TCRF) treatment of the septal swell body (SSB). This report provides results from assessments of the long‐term safety and efficacy of TCRF treatment of SSB hypertrophy to treat NAO through 12 months posttreatment.
Methods
This prospective, multicenter, long‐term, open‐label study was conducted in nine centers within the United States and included patients with severe/extreme NAO attributed to SSB hypertrophy. Outcome measures included assessments of Nasal Obstruction Symptom Evaluation Score (NOSE), Numeric Rating Scale (NRS) ease‐of‐breathing, patient satisfaction, and adverse events at 6 and 12 months.
Results
Of the 70 patients treated, 65 and 62 patients completed the 6‐ and 12‐month follow‐up assessments. Compared to baseline, there was a 67.5% decrease in adjusted mean NOSE scores at 6 months (mean change −49.6, 95% confidence interval [CI] −54.8 to −44.4; p < 0.001) and a 65.4% decrease at 12 months (mean change −48.1, 95% CI −53.7 to −42.5); p < 0.001), which is consistent with previously published 3‐month results. A 62.0% and 62.5% improvement compared to baseline was observed in the NRS ease‐of‐breathing score at 6 and 12 months, respectively ( p < 0.001). No serious adverse were reported overall and no new device‐ or procedure‐related adverse events were reported in the interval between 3 and 12 months posttreatment.
Conclusion
TCRF treatment of SSB hypertrophy has a significant and durable effect on improving the symptoms of NAO and health‐related quality of life in patients with symptoms of nasal obstruction and congestion through 12 months postprocedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chicago Nasal & Sinus Center, Chicago, Illinois, USA.
- Madison ENT & Facial Plastic Surgery, New York, New York, USA.
- Alamo ENT Associates, San Antonio, Texas, USA.
- Colorado ENT & Allergy, Colorado Springs, Colorado, USA.
- Mount Sinai Hospital, New York, New York, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Ahmad R Sedaghat
Förderung
- Aerin Medical
Zitieren
APA
Pritikin, J., Silvers, S., Rosenbloom, J., Davis, B., Signore, A. D., Sedaghat, A. R., Tajudeen, B. A., Schmale, I., & Chandra, R. (2024). Twelve‐month outcomes following temperature‐controlled radiofrequency treatment of the septal swell body for nasal airway obstruction. International Forum of Allergy & Rhinology, 14(10), 1549-1557. https://doi.org/10.1002/alr.23383
Vancouver
Pritikin J, Silvers S, Rosenbloom J, Davis B, Signore AD, Sedaghat AR, et al. Twelve‐month outcomes following temperature‐controlled radiofrequency treatment of the septal swell body for nasal airway obstruction. International Forum of Allergy & Rhinology. 2024;14(10):1549-1557. doi:10.1002/alr.23383
BibTeX
@article{Pritikin2024,
author = {Pritikin, Jordan and Silvers, Stacey and Rosenbloom, Jeffrey and Davis, Bryan and Signore, Anthony Del and Sedaghat, Ahmad R and Tajudeen, Bobby A and Schmale, Isaac and Chandra, Rakesh},
title = {Twelve‐month outcomes following temperature‐controlled radiofrequency treatment of the septal swell body for nasal airway obstruction},
journal = {International Forum of Allergy & Rhinology},
year = {2024},
volume = {14},
number = {10},
pages = {1549--1557},
doi = {10.1002/alr.23383}
}
EUVIMED